Drugs / VENSOBAFUSP ALFA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05490017 | Dec 2020 → May 2022 | paroxysmal nocturnal hemoglobinuria | Kira Pharmacenticals (US), LLC. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05517980 | Mar 2025 → Mar 2026 overdue | glomerulonephritis | Kira Pharmacenticals (US), LLC. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05504187 | Mar 2025 → Mar 2026 overdue | systemic lupus erythematosus | Kira Pharmacenticals (US), LLC. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05476887 | Nov 2022 → Nov 2024 overdue | paroxysmal nocturnal hemoglobinuria | Kira Pharmacenticals (US), LLC. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VENSOBAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314785 ↗ |
| Known as | KP104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05517980 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314785 ↗ |
| Route | Intravenous | “KP104 intravenously” NCT05476887 ↗ |